Metachromatic leukodystrophy: Case study in a child-adolescent patient
DOI:
https://doi.org/10.33448/rsd-v14i9.49562Keywords:
Arylsulfatase A Deficiency, Cerebroside Sulfatase, Neurodegeneration, ICD-10 (E75.2).Abstract
Metachromatic leukodystrophy (MLD) is a rare autosomal recessive disorder affecting the white matter of the nervous system, caused by mutations in the ARSA gene, which encodes the enzyme arylsulfatase A. This condition leads to progressive loss of motor, cognitive, and sensory functions. The objective of this study is to present a qualitative analysis, of descriptive and exploratory nature, on MLD, primarily based on a clinical case study of a child-adolescent patient, complemented by a literature review. The research addresses genetic aspects, early diagnosis, clinical and therapeutic implications, as well as the main challenges faced in the management of the disease. Articles were selected from PubMed, Scielo, and Google Scholar, focusing on clinical progression and available therapies, along with interviews with the patient’s family and analysis of laboratory and imaging exams. The study aims to clarify the difficulties faced by patients and families, providing relevant data to improve diagnostic and treatment strategies. The case analysis, given the patient’s severe and irreversible prognosis, highlights the clinical complexity and psychosocial impact of juvenile MLD, emphasizing the need for early diagnosis and multidisciplinary follow-up. Despite advances in gene therapy and stem cell transplantation, current management remains limited, underscoring the importance of research to expand therapeutic options and improve patient quality of life. This study involves human research and was approved by the ethics committee under the Certificate of Presentation and Ethical Appreciation (CAAE): 87542425.0.0000.5539.
References
Álvarez, P.; Jiménez, J.; et al. (2019). Leucodistrofia Metacromática Infantil-tardía. Presentacíon de um caso. Laurence. Sociedad Argentina de Pediatria, 117, 52-55.
Araujo, C. B.; Teixeira, C. A.; Galvão, B. P.; Tan, B. C.; Nogueira, C. N.; Pesquero, B. O.; & Vargas, N. C. M. (2022). Ataxias hereditárias autossômicas recessivas: uma revisão narrativa. Jornal Paranaense de Pediatria, 23 (1), 01-09.
Artigalas, O. A. P. (2009). Leucodistrofia metacromática: caracterização epidemiológica, bioquímica e clínica de pacientes brasileiros. Repositório digital LUME, UFRGS.
Bardin, L. (1977). Análise de conteúdo. 2. ed. Lisboa: Edições 70.
Beerepoot, S.; et al. (2019). Neuropatia periférica na leucodistrofia metacromática: situação atual e perspectiva futura. Orphanet Journal of Rare Diseases, 14, 240.
Bellettato, C. M., & Scarpa, M. (2018). Possible strategies to cross the blood-brain barrier. Italian Journal of Pediatrics, 44(2), 131.
Cesani, M.; Lorioli, L.; Grossi, S.; Amico, G.; Fumagalli, F.; Spiga, I.; et al. (2016). Atualização de mutação dos genes ARSA e PSAP causando leucodistrofia metacromática. Human Mutation, 37, 16–27.
Espejo, L. M.; de la Espriella, R.; & Hernández, J. F. (2017.). Metachromatic leukodystrophy: Case presentation. Revista Colombiana de Psiquiatria, 46 (1): 44-49
Kubaski, F.; Herbst, Z.; Burin, M.; Michelin-Tilleri, K.; et al. (2022). Dosagem de sulfatídeos no sobrenadante do líquido amniótico: Uma ferramenta útil no diagnóstico pré-natal da leucodistrofia metacromática. JIMD Reports, 63(2), 161–167.
Muraleedharan, A.; & Vanderperre, B. (2023). The endo-lysosomal system in Parkinson's disease: expanding the horizon. Journal of Molecular Biology, 435 (12), 168140.
Orchard, P. J., & Tolar, J. (2010). Transplant outcomes in leukodystrophies. Seminars in Hematology, 47(1), 70–78.
Pedri, A. F.; Guedes, M. S.; & Castro, C. C. (2022). Classificação das doenças neurometabólicas hereditárias baseada em aspectos radiológicos: Ensaio iconográfico. Radiologia Brasileira, 55(2), 113–119.
Pereira, A. S. et al. (2018). Metodologia da pesquisa científica. [free ebook]. Santa Maria. Editora da UFSM.
Raina, A., Nair, S. S., Nagesh, C., Thomas, B., Nair, M., & Sundaram, S. (2019). Electroneurography and advanced neuroimaging profile in pediatric-onset metachromatic leukodystrophy. Journal of Pediatric Neurosciences, 14(2), 70–75.
Sajjad, M. M.; & Yousaf, S. (2021). A case report of juvenile form of metachromatic leukodystrophy. Pakistan Armed Forces Medical Journal, 71(6), 2255–2256.
Shaimardanova, A. A.; Chulpanova, D. S.; Solovyeva, V. V.; Mullagulova, A. I.; Kitaeva, K. V.; Allegrucci, C.; & Rizvanov, A. A. (2020). Metachromatic leukodystrophy: Diagnosis, modeling, and treatment approaches. Frontiers in Medicine (Lausanne), 7, 576221.
Sessa, M.; et al. (2016). Terapia genética com células-tronco hematopoiéticas lentivirais na leucodistrofia metacromática de início precoce: uma análise ad-hoc de um ensaio clínico não randomizado, aberto, de fase 1/2. The Lancet, 388 (10043), 476-487.
Tade Clínica Gem. (2024). Como reconhecer as principais sequências da ressonância magnética. https://www.tadeclinicagem.com.br/blog/como-reconhecer-as-principais-sequencias-da-ressonancia-magnetica/
Thibert, K. A.; Raymond, G. V.; Tolar, J.; Miller, W. P.; Orchard, P. J.;& Lund, T. C. (2016). Cerebral spinal fluid levels of cytokines are elevated in patients with metachromatic leukodystrophy. Scientific Reports, 6, 24579.
Toassi, R. F. C. & Petry, P. C. (2021). Metodologia científica aplicada à área de saúde. (2.ed). Editora da UFRGS.
Uddin, M. A.; Islam, A.; Hoque, S. K. A.; & Saha, N. (2018). Juvenile metachromatic leukodystrophy: A case report from Bangladesh. Journal of National Institute of Neurosciences Bangladesh, 4(2), 154–157.
Universidade Estadual de Campinas. (2017). RPG Metacromática. https://anatpat.unicamp.br/rpgmeta20.html
Veldt, V.; Rappard, V.; et al. (2019). Intrathecal baclofen in metachromatic leukodystrophy. Developmental Medicine & Child Neurology, 61, 232-235.
Zerah, M., Piguet, F., Colle, M. A., Raoul, S., Deschamps, J. Y., Deniaud, J., Gautier, B., Toulgoat, F., Bieche, I., Laurendeau, I., Sondhi, D., Souweidane, M. M., Cartier-Lacave, N., Moullier, P., Crystal, R. G., Roujeau, T., Sevin, C., & Aubourg, P. (2015). Intracerebral gene therapy using AAVrh.10-hARSA recombinant vector to treat patients with early-onset forms of metachromatic leukodystrophy: Preclinical feasibility and safety assessments in nonhuman primates. Human Gene Therapy Clinical Development, 26(2), 113–124.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ana Rubia Simão Morgan, Michele Andressa Vier Wolski
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
